scholarly journals Liquid Argon Time Projection Chamber research and development in the United States

2014 ◽  
Vol 9 (05) ◽  
pp. T05005-T05005 ◽  
Author(s):  
B Baller ◽  
C Bromberg ◽  
N Buchanan ◽  
F Cavanna ◽  
H Chen ◽  
...  
Keyword(s):  
United States ◽  
Research And Development ◽  
Time Projection Chamber ◽  
Liquid Argon ◽  
The United States ◽  
Time Projection

scholarly journals Summary of the second workshop on liquid argon time projection chamber research and development in the United States

2015 ◽  
Vol 10 (07) ◽  
pp. T07006-T07006 ◽  
Author(s):  
R. Acciarri ◽  
M. Adamowski ◽  
D. Artrip ◽  
B. Baller ◽  
C. Bromberg ◽  
...  
Keyword(s):  
United States ◽  
Research And Development ◽  
Time Projection Chamber ◽  
Liquid Argon ◽  
The United States ◽  
Time Projection

A History of Geothermal Energy Research and Development in the United States. Reservoir Engineering 1976-2006

2010 ◽  
Author(s):  
B. Mack Kennedy ◽  
Karsten Pruess ◽  
Marcelo J. Lippmann ◽  
Ernest L. Majer ◽  
Peter E. Rose ◽  
...  
Keyword(s):  
United States ◽  
Research And Development ◽  
Geothermal Energy ◽  
The United States ◽  
Reservoir Engineering ◽  
Energy Research ◽  
History Of

A HISTORICAL REVIEW OF THE ACCOUNTING TREATMENT OF RESEARCH AND DEVELOPMENT COSTS

1992 ◽  
Vol 19 (1) ◽  
pp. 51-78 ◽  
Author(s):  
Paul E. Nix ◽  
David E. Nix
Keyword(s):  
United States ◽  
Research And Development ◽  
Alternative Treatment ◽  
Historical Review ◽  
The United States ◽  
Current Treatment ◽  
Social Consequences ◽  
Financial Accounting ◽  
Development Costs ◽  
Accounting Rules

This study reviews the literature and the practice of accounting for research and development (R&D) costs from the first reference in 1917 to the current treatment. The conceptual treatment of R&D is compared to current financial accounting rules and explanation of the evolution of the current rules is presented. The economic and social consequences of the current rules which require R&D costs to be expressed are examined. The paper explores possible alternative treatment of R&D costs. As a contrast to U.S. practice, the accounting treatment of R&D costs in other countries is discussed. Given the findings of this paper, a strong case can be made for changing the way that R&D costs are accounted for in the United States.

Pharmaceutical Innovation in the United States: Factors Affecting Future Performance

1993 ◽  
Vol 9 (2) ◽  
pp. 167-173 ◽  
Author(s):  
Michael R. Pollard
Keyword(s):  
United States ◽  
Pharmaceutical Industry ◽  
Research And Development ◽  
Cost Containment ◽  
The United States ◽  
Private Companies ◽  
Factors Affecting ◽  
The Past ◽  
Future Performance ◽  
Regulatory Strategy

AbstractFueled by high returns on its investments, the pharmaceutical industry in the United States has flourished for the past 50 years. The regulatory strategy of demanding stringent testing then allowing market-based pricing has allowed private companies to fund ambitious research and development activities with the assurance that these investments will be recovered. However, aggressive managed-care cost-containment strategies threaten the companies' ability to recoup research and development expenses and may affect their willingness to invest in future innovative research.

A large scale purification system for a liquid argon time projection chamber

1987 ◽  
Vol 258 (2) ◽  
pp. 170-176 ◽  
Author(s):  
Peter J. Doe ◽  
Richard C. Allen ◽  
Steven D. Biller ◽  
Gerhard Bühler ◽  
Wayne A. Johnson ◽  
...  
Keyword(s):  
Time Projection Chamber ◽  
Large Scale ◽  
Liquid Argon ◽  
Purification System ◽  
Time Projection
Sign in / Sign up

Export Citation Format

Share Document